Octagon Capital Advisors LP Has $12.30 Million Position in Precision BioSciences, Inc. $DTIL

Octagon Capital Advisors LP raised its stake in shares of Precision BioSciences, Inc. (NASDAQ:DTIL) by 16.6% in the first quarter, according to the company in its most recent disclosure with the SEC. The firm owned 2,236,732 shares of the company’s stock after acquiring an additional 318,737 shares during the quarter. Precision BioSciences makes up 1.4% of Octagon Capital Advisors LP’s portfolio, making the stock its 21st largest holding. Octagon Capital Advisors LP owned about 0.09% of Precision BioSciences worth $12,302,000 as of its most recent filing with the SEC.

Several other institutional investors and hedge funds also recently made changes to their positions in the company. Empery Asset Management LP bought a new stake in shares of Precision BioSciences in the 4th quarter worth about $9,130,000. Aberdeen Group plc bought a new position in Precision BioSciences during the 4th quarter valued at about $8,897,000. Boothbay Fund Management LLC lifted its holdings in Precision BioSciences by 497.1% during the 4th quarter. Boothbay Fund Management LLC now owns 1,066,050 shares of the company’s stock valued at $4,435,000 after purchasing an additional 887,515 shares during the last quarter. Alyeska Investment Group L.P. acquired a new position in Precision BioSciences in the fourth quarter valued at about $3,320,000. Finally, Affinity Asset Advisors LLC acquired a new position in Precision BioSciences in the first quarter valued at about $3,289,000. Institutional investors and hedge funds own 37.99% of the company’s stock.

Analyst Upgrades and Downgrades

Several analysts have recently weighed in on the stock. JonesTrading reaffirmed a “buy” rating and set a $30.00 price objective on shares of Precision BioSciences in a report on Friday, April 17th. Weiss Ratings raised Precision BioSciences from a “sell (e+)” rating to a “sell (d-)” rating in a report on Friday, May 8th. HC Wainwright restated a “buy” rating on shares of Precision BioSciences in a research report on Thursday, July 9th. Finally, Oppenheimer began coverage on Precision BioSciences in a report on Tuesday, June 9th. They set an “outperform” rating and a $20.00 price target for the company. Four analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $32.25.

Precision BioSciences Stock Performance

DTIL opened at $7.29 on Monday. Precision BioSciences, Inc. has a 1-year low of $3.53 and a 1-year high of $9.62. The stock has a market capitalization of $188.08 million, a PE ratio of -1.99 and a beta of 1.25. The company has a current ratio of 14.02, a quick ratio of 14.02 and a debt-to-equity ratio of 0.29. The firm has a 50-day moving average price of $7.35 and a two-hundred day moving average price of $6.13.

Precision BioSciences (NASDAQ:DTIL) last posted its quarterly earnings data on Tuesday, May 5th. The company reported ($0.75) earnings per share for the quarter, missing the consensus estimate of ($0.66) by ($0.09). Precision BioSciences had a negative return on equity of 85.37% and a negative net margin of 96.73%.The company had revenue of $10.84 million during the quarter, compared to the consensus estimate of $4.05 million. As a group, equities analysts anticipate that Precision BioSciences, Inc. will post -2.21 earnings per share for the current fiscal year.

Precision BioSciences Profile

Precision BioSciences is a clinical‐stage genome editing company that leverages its proprietary ARCUS platform to develop targeted gene therapies. ARCUS, an engineered nuclease derived from a naturally occurring enzyme, enables precise DNA modifications for both in vivo and ex vivo applications. The company’s pipeline spans genetic diseases—including rare monogenic disorders—and immuno‐oncology, where it is advancing allogeneic cell therapy candidates designed to address hematologic malignancies and solid tumors.

Founded in 2006 as a spin‐out from research at the University of North Carolina, Precision BioSciences is headquartered in Durham, North Carolina, with additional research and manufacturing capabilities located in the Research Triangle Park area.